Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era.

Journal of neuro-oncology - 1 Sept 2024

Cole Kyril L, Earl Emma R, Findlay Matthew C, Sherrod Brandon A, Tenhoeve Samuel A, Kunzman Jessica, Cannon Donald M, Akerley Wallace, Burt Lindsay, Seifert Seth B, Goldman Matthew, Jensen Randy L

Abstract excerpt

PURPOSE: Targeted treatment options for non-small cell lung cancer (NSCLC) brain metastases (BMs) may be combined with stereotactic radiosurgery (SRS) to optimize survival. We assessed patient outcomes after SRS for NSCLC BMs, identifying survival trajectories associated with targetable mutations. METHODS: In this retrospective time-dependent analysis, we analyzed median overall survival of patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Prognosis

Share to Radiosurgery

Share to Survival Rate

Source

Identifiers

PMID: 38951457
DOI: 10.1007/s11060-024-04749-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era.PMID 38951457Read ↗

Assessing Survival in Non-Small Cell Lung Cancer Brain Metastases After Stereotactic Radiosurgery: Before and After the Start of the Targetable Mutation EraSemantic proximity Read ↗

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.Semantic proximity Read ↗

EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.Semantic proximity Read ↗

Converging Survival Trends in Non-Small Cell Lung Cancer Patients With and Without Brain Metastasis Receiving State-of-the-Art TreatmentSemantic proximity Read ↗

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.Semantic proximity Read ↗

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.Semantic proximity Read ↗

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.